| [1] |
BEUERS U, GERSHWIN ME, GISH RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'[J]. J Hepatol, 2015, 63(5): 1285-1287. DOI: 10.1016/j.jhep.2015.06.031. |
| [2] |
DUAN WJ, LYU TT, CHEN S, et al. Clinical features and prognosis of autoimmune hepatitis with antimitochondrial antibody posistive[J]. J Clin Exp Med, 2022, 21(18): 1931-1934. DOI: 10.3969/j.issn.1671-4695.2022.18.008. |
| [3] |
TO U, SILVEIRA M. Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 603-611. DOI: 10.1016/j.cld.2018.03.010. |
| [4] |
JIANG Y, XU BH, RODGERS B, et al. Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome[J]. J Clin Transl Hepatol, 2021, 9(3): 392-398. DOI: 10.14218/JCTH.2021.00008. |
| [5] |
CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J]. Hepatology, 1998, 28(2): 296-301. DOI: 10.1002/hep.510280203. |
| [6] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. DOI: 10.1016/j.jhep.2009.04.009. |
| [7] |
WANG Q, SELMI C, ZHOU X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis[J]. J Autoimmun, 2013, 41: 140-145. DOI: 10.1016/j.jaut.2012.10.004. |
| [8] |
ZHANG JF, XU HM, SONG HY, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome: poor diagnostic sensitivity of Paris' criteria in Chinese patients[J]. J Prac Hepatol, 2019, 22(4): 537-540. DOI: 10.3969/j.issn.1672-5069.2019.04.022. |
| [9] |
Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 35-41. DOI: 10.3760/cma.j.cn112138-20211112-00794 |
| [10] |
HEURGUÉ A, VITRY F, DIEBOLD MD, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease[J]. Gastroenterol Clin Biol, 2007, 31(1): 17-25. DOI: 10.1016/s0399-8320(07)89323-7. |
| [11] |
FAN X, ZHU Y, MEN R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: A real-world study[J]. Can J Gastroenterol Hepatol, 2018, 2018: 1965492. DOI: 10.1155/2018/1965492. |
| [12] |
CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406. DOI: 10.1016/j.jhep.2005.10.017. |
| [13] |
ANNIBALE B, ESPOSITO G, LAHNER E. A current clinical overview of atrophic gastritis[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(2): 93-102. DOI: 10.1080/17474124.2020.1718491. |
| [14] |
LANDGREN AM, LANDGREN O, GRIDLEY G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans[J]. Cancer, 2011, 117(6): 1163-1171. DOI: 10.1002/cncr.25524. |
| [15] |
JENSEN MD, JEPSEN P, VILSTRUP H, et al. Increased cancer risk in autoimmune hepatitis: A Danish Nationwide Cohort Study[J]. Am J Gastroenterol, 2022, 117(1): 129-137. DOI: 10.14309/ajg.0000000000001525. |
| [16] |
SHARMA R, VERNA EC, SIMON TG, et al. Cancer risk in patients with autoimmune hepatitis: A nationwide population-based cohort study with histopathology[J]. Am J Epidemiol, 2022, 191(2): 298-319. DOI: 10.1093/aje/kwab119. |
| [17] |
|
| [18] |
YANG MM, ZHOU L, LIN R, et al. Clinical characteristics and the incidence of extrahepatic autoimmune disease and malignant tumor in primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J]. Chin J Dig, 2013, 33(9): 596-600. DOI: 10.3760/cma.j.issn.0254-1432.2013.09.004. |
DownLoad:
